Non-Cystic Fibrosis Bronchiectasis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farma
The Non-Cystic Fibrosis Bronchiectasis (NCFB) market is projected to reach USD 5,768 million by 2034, growing at a CAGR of 16.25%. This growth is driven by an expanding pipeline, including therapies like Insmed's approved brensocatib and Boehringer Ingelheim's verducatib in Phase III. Increased awareness and improved diagnostic techniques are also contributing to the rising prevalence of NCFB, with significant market sizes noted in the US, EU4, UK, and Japan.
Martina Flammer reports multiple INSM (NASDAQ: INSM) share dispositions in Form 144
Insmed Inc. (NASDAQ: INSM) reported Form 144 filings detailing insider sales by Martina Flammer, involving multiple dispositions of common stock between May 11, 2026, and June 5, 2026. These transactions, labeled as "Stock Plan Activity," include sales of 12,949 shares, 7,854 shares, 10,479 shares, 2,566 shares, and 1,858 shares on respective dates. The filing specifies transaction dates and share counts but does not provide information on proceeds, prices, or remaining beneficial ownership.
Insmed Q1 2026 slides: BRINSUPRI surges 44%, ARIKAYCE expansion ahead
Insmed's Q1 2026 results showed strong commercial performance for BRINSUPRI, with global net revenues surging 44% sequentially, and promising Phase 3b ENCORE trial results for ARIKAYCE, suggesting a significant label expansion. Despite exceeding analyst expectations on revenue and EPS, the stock tumbled due to ongoing investor concerns about the company's path to profitability. Insmed is confident in achieving cash flow positivity by 2027 and is advancing multiple pipeline programs, including TPIP and gene therapies.
INSM - Insmed Inc Options
This article provides a detailed financial overview of Insmed Inc (INSM), including its stock performance, market capitalization, earnings per share, sales figures, and various financial ratios. It also lists key statistics like insider ownership, institutional ownership, and analyst recommendations. The data is presented as of June 30, with a last close price of $106.62.
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 2500 Growth Benchmark
Insmed Incorporated (NasdaqGS: INSM) has been removed from the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This news follows several other index removals for Insmed in late June, including from the Russell Small Cap Comp Value Benchmark, Russell 3000 Value Benchmark, and NASDAQ-100 Index. Despite these changes, analyst sentiment remains positive, with an average target price of $197.05, suggesting an 88.13% upside from its last close price of $104.74.
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors
Insmed (INSM), First Solar (FSLR), and Aptiv (APTV) have each experienced a "death cross," a bearish technical signal where the 50-day moving average falls below the 200-day moving average, signaling potential long-term downtrends. Despite this, Wall Street analysts maintain a bullish outlook, projecting significant upside for all three stocks. The article details the technical signals, company-specific factors, and analyst ratings for each, emphasizing that while retail sentiment is turning bearish, professional analysts still see strong growth potential.
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 3000 Value Benchmark
Insmed Incorporated (NasdaqGS: INSM), a biopharmaceutical company, has been removed from the Russell 3000 Value Benchmark, according to an announcement on June 28, 2026. This news follows several other recent drops from various Russell indexes and the NASDAQ-100. The company specializes in drugs for metabolic diseases, endocrine disorders, and respiratory conditions, with key products ARIKAYCE® and BRINSUPRI®.
Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)
Mizuho has reaffirmed its Outperform rating on Insmed Incorporated (INSM) despite lowering its price target to $192 from $202, seeing the recent 29% selloff as a buying opportunity. The firm expressed continued confidence in Insmed and its product BRINSUPRI. Additionally, Insmed announced the appointment of Samuele Butera as Senior Vice President and General Manager, Global Respiratory, to lead the launch of BRINSUPRI and advance other pipeline candidates.
Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)
Mizuho reiterated an Outperform rating on Insmed Incorporated (INSM) despite lowering its price target to $192 from $202, calling the recent stock selloff a buying opportunity. The firm expressed continued confidence in the company and its BRINSUPRI product. Additionally, Insmed announced the appointment of Samuele Butera as Senior Vice President and General Manager, Global Respiratory, to lead the launch of BRINSUPRI and advance other pipeline candidates.
Insmed Insider Sold Shares Worth $2,210,763, According to a Recent SEC Filing
An insider at Insmed Incorporated sold shares valued at $2,210,763, as reported in a recent SEC filing. This transaction occurred on June 26, 2026. This news follows several other updates for Insmed, including a change in executive leadership and analyst rating adjustments.
INSMED (INSM) CEO Lewis exercises options and sells 21,398 shares under 10b5-1 plan
INSMED Inc. CEO William Lewis exercised stock options for 21,398 shares and simultaneously sold an equivalent number of shares under a pre-arranged Rule 10b5-1 trading plan. The sales occurred on June 25, 2026, at weighted average prices ranging from approximately $101.78 to $106.45 per share. Following these transactions, Lewis maintains significant direct and indirect holdings in INSMED, totaling over 500,000 shares.
Price to earnings forward of Insmed Incorporated – NASDAQ:INSM
This page provides financial information for Insmed Incorporated (NASDAQ: INSM), focusing on its forward price-to-earnings ratio. It is a data-oriented page from TradingView, offering details on the company's financial metrics within the Pharmaceuticals: Major sector.
Enterprise value to revenue forward of Insmed Incorporated – SWB:IM8N
This page provides financial information for Insmed Incorporated (SWB:IM8N) on the Stuttgart Stock Exchange, focusing on its enterprise value to revenue forward. It appears to be a financial data portal displaying key metrics for the pharmaceutical company. The content primarily shows navigation elements and links to various financial tools and community features.
Form 144 INSMED INC For: 25 June By Investing.com
This article reports on the filing of Form 144 for INSMED INC on June 25, 2026. The content provides basic financial market data, including stock market indices, commodities, and bond performance, but offers no specific details about the Form 144 filing itself. The article is primarily a data placeholder on Investing.com.
Is Insmed (INSM) Cheap Following The EMBARC Partnership And Upcoming TPIP Data?
Insmed (INSM) is gaining investor attention due to a new partnership with EMBARC for a brensocatib study and upcoming TPIP lung drug data. Despite recent share price fluctuations, the stock appears significantly undervalued according to analyst targets and intrinsic value estimates, suggesting a potential buying opportunity. However, regulatory delays or payer pushback on pricing could impact its future growth.
Form 144 INSMED INC For: 25 June By Investing.com
This article reports on the filing of Form 144 for INSMED INC on June 25, 2026. Form 144 is a notice of the intent to sell restricted securities. The article includes the stock symbol INSM and states that it saw a 0.98% increase.
Enterprise value to EBITDA forward of Insmed Incorporated – NASDAQ:INSM
This article provides a brief financial overview of Insmed Incorporated (NASDAQ: INSM), focusing on its enterprise value to EBITDA forward metric. The content highlights the company's stock information and indicates the type of financial data available for the company on the platform. It also lists various features and services offered by TradingView.
William Lewis files Form 144 — Insmed (NASDAQ: INSM) reports recent share dispositions
Insmed Inc. insider William Lewis has filed a Form 144, indicating proposed dispositions of Common Stock. This filing details several share sales under "Securities Sold During The Past 3 Months," including transactions on June 8, 2026 (6,515 shares) and June 3, 2026 (7,605 shares), along with earlier sales in May and April 2026. A Form 144 serves as an administrative notice of intent to sell restricted or control securities under Rule 144, but does not confirm the completion or proceeds of these transactions.
Enterprise value to EBIT forward of Insmed Incorporated – SWB:IM8N
This article provides forward-looking enterprise value to EBIT data for Insmed Incorporated (SWB:IM8N). No specific financial figures are detailed, but the article focuses on this key financial metric for the pharmaceutical company trading on the Stuttgart Stock Exchange. It indicates that the data is presented without further analysis or context within the brief content.
Insmed names Butera SVP, general manager, global respiratory
Insmed Inc., a global biopharmaceutical company, has appointed Samuele Butera as Senior Vice President, General Manager, Global Respiratory. Butera will lead the company's respiratory therapeutic area and report directly to the CEO, Will Lewis. He brings over two decades of commercial leadership experience from companies like Johnson & Johnson and Novartis.
Non-Cystic Fibrosis Bronchiectasis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmace
DelveInsight's report details the Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline, highlighting over 12 companies developing more than 15 therapies. Key developments include the FDA approval of Insmed’s brensocatib (Brinsupri) as the first therapy for NCFB and Boehringer Ingelheim's positive Phase II data for verducatib, a potential competitor. The report covers the global clinical development landscape, therapeutic assessments, and market dynamics for NCFB treatments.
EMBARC Announces Its Intention to Collaborate with Insmed
EMBARC, a leading European research network, announced its intention to collaborate with Insmed on a landmark interventional study. The study will evaluate brensocatib 25 mg in approximately 3,000 bronchiectasis patients across Europe over three years, aiming to understand its long-term use and potential to modify the disease course. This research will expand on existing evidence that brensocatib slows lung function decline and will investigate if earlier intervention can further alter the disease's trajectory.
Form 4 Insmed Inc For: 24 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Insmed Inc. as of June 24th. It primarily serves as a placeholder for the filing information, with the company's stock symbol INSM mentioned alongside its daily performance. The page also includes various market data and other news headlines.
Form 4 Insmed Inc For: 24 June By Investing.com
The article, titled "Form 4 Insmed Inc For: 24 June," is a concise report from Investing.com indicating a Form 4 filing for Insmed Inc. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's stock by an insider. The article explicitly mentions that Insmed Inc. (INSM) is up 0.98%.
INSMED Inc (NASDAQ: INSM) CLO sells 1,806 shares under 10b5-1 plan
INSMED Inc's Chief Legal Officer, Michael Alexander Smith, sold 1,806 shares of common stock at $95.82 per share under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following this transaction, Smith directly holds 37,648 shares of INSMED Inc Common Stock. The sale, valued at $173,051, was executed as an open-market transaction.
Insmed (NASDAQ: INSM) awards RSUs and stock options to SVP
Insmed (NASDAQ: INSM) has granted its Senior Vice President, Samuele Butera, new equity awards as part of his compensation. These awards include 7,342 Restricted Stock Units (RSUs) and stock options for 12,570 shares, with an exercise price of $102.15 per share. Both RSUs and stock options have multi-year vesting schedules, with RSUs vesting over four years and options vesting over approximately three years.
Insmed (INSM) SVP Samuele Butera files Form 3 showing no trades
Insmed (INSM) Senior Vice President (SVP), GM, Global Respiratory, Samuele Butera, has filed a Form 3, an initial statement of beneficial ownership, with the SEC. The filing indicates that Butera currently holds no beneficial ownership of Insmed securities, with zero transactions reported for buys, sells, acquisitions, or dispositions, and no derivative positions. This filing confirms his new position with the company but shows no immediate change in his stock holdings.
Press Release: Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
Insmed has appointed Samuele Butera as Senior Vice President, General Manager, Global Respiratory. This key leadership role will focus on global commercial strategy and operations for the company's respiratory portfolio. Butera brings significant experience from major pharmaceutical companies like Novartis and GlaxoSmithKline.
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
Insmed Incorporated announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective June 23, 2026. In this new role, Mr. Butera will lead Insmed's Respiratory Therapeutic Area and serve on the Executive Committee. He brings over two decades of commercial leadership experience, having held senior roles at Johnson & Johnson and Novartis, and will be instrumental in the launch of BRINSUPRI, expansion of ARIKAYCE's label, and TPIP development program.
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
Insmed Incorporated announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective June 23, 2026. Mr. Butera will lead Insmed's Respiratory Therapeutic Area and serve on the Executive Committee, reporting to CEO Will Lewis. He brings over two decades of commercial leadership experience from companies like Johnson & Johnson and Novartis, where he spearheaded significant product launches and business growth.
Insmed Appoints Samuele Butera to Lead Global Respiratory Business
Insmed has appointed Samuele Butera as Senior Vice President and General Manager, Global Respiratory, to lead its expanding respiratory portfolio. Butera brings over 20 years of experience from Johnson & Johnson and Novartis, where he spearheaded major product launches. His appointment comes as Insmed continues the commercial launch of BRINSUPRI, seeks a label expansion for ARIKAYCE, and advances its TPIP development program, marking a pivotal moment for the company's focus on respiratory diseases.
Insmed taps Johnson & Johnson veteran to lead its respiratory push
Insmed (Nasdaq: INSM) has appointed Samuele Butera as its Senior Vice President and General Manager, Global Respiratory, effective June 23, 2026. Butera, with over two decades of commercial leadership experience from companies like Johnson & Johnson and Novartis, will lead Insmed's Respiratory Therapeutic Area, reporting to CEO Will Lewis. His expertise is expected to significantly contribute to the launch of BRINSUPRI, the potential expansion of ARIKAYCE's label, and the TPIP development program.
Insmed appoints Samuele Butera to lead respiratory division
Insmed has appointed Samuele Butera as Senior Vice President and General Manager of Global Respiratory. Butera brings over 20 years of commercial leadership experience from companies like Johnson & Johnson and Novartis, where he led significant product launches. This appointment comes as Insmed, a biopharmaceutical company with a $21.4 billion market capitalization, anticipates continued sales growth despite being unprofitable, with various analyst firms adjusting price targets and ratings based on competitive risks and product performance.
Michael Smith files Form 144 listing multiple INSM share sales (INSM)
Michael Smith, an insider at Insmed Inc (INSM), has filed a Form 144 disclosing proposed sales of common stock. The filing indicates multiple dispositions of shares on various dates between March and June 2026, alongside an issuer stock plan activity. This is a routine regulatory notice of intended dispositions, without details on sales prices or proceeds.
What's Driving Insmed's Recent Volatility
Insmed (INSM) shares have experienced significant volatility following their Q1 2026 earnings report, which saw a revenue miss but an EPS beat and reaffirmed strong full-year guidance. Despite Darwin Global Management reducing its substantial holding in Insmed, the company remains its largest position, and Wall Street analysts largely maintain a bullish stance with a median price target of $165.0, citing strong product performance and a promising pipeline as key drivers for potential upside. However, the stock's high Price-to-Sales ratio and consistent insider selling suggest inherent risks, balancing the significant opportunities with potential execution challenges.
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk
The article discusses three large US pharmaceutical stocks—Insmed, Viatris, and BioMarin Pharmaceutical—that are significantly exposed to current drug policy changes, particularly the US Section 301 trade investigation into Germany’s pharmaceutical pricing. It examines how these companies' cash flows could be affected by potential tariffs and market access issues in Europe. The analysis highlights their respective business models, global reach, and the intersection of clinical developments, pricing strategies, and geopolitical risks.
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk
A Section 301 trade investigation into Germany’s pharmaceutical pricing has put drug policy in the spotlight, affecting US pharmaceutical companies. This article examines three large US pharmaceutical stocks—Insmed (INSM), Viatris (VTRS), and BioMarin Pharmaceutical (BMRN)—that are particularly exposed to these developments, highlighting their cash flow dynamics, pricing risks, and potential investment implications. It encourages investors to consider how current headlines might support or argue against an investment case for these companies.
InvestingPro’s Fair Value spotted Insmed’s 44% drop before it happened By Investing.com
InvestingPro's Fair Value models successfully predicted a 44.5% stock drop for Insmed (NASDAQ:INSM) six months before it occurred, warning of significant overvaluation in December 2025. Despite revenue growth, the biotech company remained unprofitable, faced competitive pressures, and saw analyst downgrades and insider selling. Even after the decline, InvestingPro's current Fair Value suggests Insmed is still overvalued.
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst
Insmed announced positive results from a trial of its drug Arikayce for Mycobacterium avium complex (MAC) lung infection, pleasing Wall Street. Truist analyst Danielle Brill believes the data is sufficient for full FDA approval for both refractory MAC and all MAC lung disease, maintaining a 'Buy' rating and a $205 price target for INSM shares. The company plans to file for full approval and a supplemental new drug application in the second half of 2026.
Insmed Inc (INSM) Financial Health: Profitability & Balance Sheet Analysis
Insmed Inc (INSM) has a stable financial status and high operating efficiency, with a current financial score of 8.55, ranking 40th in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 229.62% to $305.96 million and a net profit increase of 36.25%. While key financial metrics such as cash and cash equivalents, total assets, liabilities, and free cash flow were not disclosed, Insmed shows strong operational efficiency and growth potential according to TradingKey's assessment.
Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates
Insmed Inc (INSM) has an earnings forecast score of 8.61, ranking 94th in the Biotechnology & Medical Research industry, with an average price target of $216.50 based on 23 analysts. The company's expected revenue for the next quarter is $389.55M, and the EPS is projected at -$0.80, improving from the previous quarter's -$1.54. Most analysts currently recommend a "Buy" for INSM stock.
Insmed Inc (INSM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed breakdown of Insmed Inc.'s (INSM) revenue by business segments and geographic regions. For a recent fiscal year ending on April 6, the company generated $433.76 million (71.53%) from Arikayce and $172.66 million (28.47%) from Brinsupri. Geographically, $452.95 million (74.69%) of revenue came from the US, while $153.47 million (25.31%) was from international markets.
Insmed Inc (INSM) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Insmed Inc (INSM), identifying major institutional holders and their proportion of shares. It also provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity with changes in holdings for key investors. Additionally, it lists several ETFs that include INSM in their portfolios.
Mizuho cuts Insmed stock price target on volatility concerns By Investing.com
Mizuho has reduced its price target for Insmed (NASDAQ:INSM) shares from $202 to $192, while maintaining an Outperform rating, due to increased investor concerns regarding stock volatility and upcoming second-quarter results for its lead asset, Brinsupri. Insmed's shares have fallen significantly since their Q1 2026 earnings report, contrasting with gains in the broader biotech index; however, the firm retains confidence in Insmed's execution and pipeline. Other analysts like RBC Capital and Truist Securities also adjusted their price targets due to various factors, while Cantor Fitzgerald and BofA Securities reiterated positive ratings.
Mizuho cuts Insmed stock price target on volatility concerns By Investing.com
Mizuho has lowered its price target for Insmed (NASDAQ: INSM) shares to $192 from $202, while maintaining an Outperform rating, due to increased investor concerns and stock volatility ahead of second-quarter results for its lead asset, Brinsupri. Despite the recent positive first-quarter 2026 earnings that surpassed Wall Street expectations, Insmed's shares have significantly underperformed the biotech index, leading to adjusted outlooks from several analysts including RBC Capital and Truist Securities. However, Mizuho, Cantor Fitzgerald, and BofA Securities remain confident in Insmed's execution and pipeline.
Insmed (INSM) Stock Valuation After Pullback And Rare Disease Pipeline Debate
Insmed (INSM) stock has pulled back, opening a debate on its valuation relative to its rare disease pipeline, including ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder. While many analysts consider it significantly undervalued with a fair value of US$200.00, driven by aggressive future revenue expectations from upcoming drug launches and positive clinical trial data, its current P/S ratio of 25.8x suggests a tougher picture compared to the biotech industry average. The company's future hinges on timely regulatory approvals and favorable payer support for its pipeline drugs.
A Blueprint For Addressing Underserved Patient Populations
This article discusses the biopharmaceutical industry's need to rethink its approach to clinical development, especially for underserved patient populations with rare or less prevalent diseases. It emphasizes understanding patient needs, incorporating patient feedback into trial design, facilitating access to care through networks of excellence, and ensuring therapies are accessible post-approval. The author calls for collective action from industry, academia, regulators, and patient groups to build a more patient-centered clinical research ecosystem.
Monashee Investment Management LLC Acquires Shares of 50,000 Insmed, Inc. $INSM
Monashee Investment Management LLC has acquired 50,000 shares of Insmed, Inc. ($INSM) during the fourth quarter, a new position valued at approximately $8.7 million, making it their fifth-largest holding. Several other institutional investors also increased their stakes, indicating continued interest in the biopharmaceutical company. Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $212.50 for Insmed.
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study
Insmed Incorporated (INSM) announced that its mid-stage study evaluating brensocatib for moderate to severe hidradenitis suppurativa failed to meet its primary and secondary goals, causing its stock to fall 2% after hours. The company will discontinue development of brensocatib for this condition. Despite the setback, analysts currently rate INSM stock as 'Buy' or higher, with a significant potential upside, and the company has two other approved therapies.
Insmed stock hits 52-week low at 90.85 USD By Investing.com
Insmed Inc. (INSM) stock has fallen to a 52-week low of $90.85, a significant decline despite the company reporting better-than-expected Q1 2026 earnings and revenue. Analysts maintain a "Strong Buy" consensus with substantial upside potential, but concerns about competitive risks persist, leading to adjusted price targets from various firms.
